Vanguard Group Inc. Trims Holdings in Evolent Health, Inc $EVH

Key Points

• Vanguard Group Inc. reduced its holdings in Evolent Health, Inc. by 2.1%, now owning approximately 9.38% of the company with shares valued at $103.6 million.
• Evolent Health reported a loss of $0.10 per share in its latest quarterly earnings, which was below the expected profit of $0.10, with a revenue drop of 31.3% year-over-year.
• Analysts have positive outlooks for Evolent Health, with target prices ranging from $13.00 to $17.93, and the stock receiving an average rating of "Buy" from several firms.

Vanguard Group Inc. reduced its stake in shares of Evolent Health, Inc (NYSE:EVH - Free Report) by 2.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,938,156 shares of the technology company's stock after selling 233,043 shares during the quarter. Vanguard Group Inc. owned 9.38% of Evolent Health worth $103,584,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Raymond James Financial Inc. purchased a new position in Evolent Health during the fourth quarter valued at approximately $2,542,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Evolent Health by 18.6% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 36,498 shares of the technology company's stock valued at $346,000 after purchasing an additional 5,712 shares during the period. Brighton Jones LLC acquired a new stake in Evolent Health in the fourth quarter valued at approximately $3,927,000. Brevan Howard Capital Management LP acquired a new stake in Evolent Health in the fourth quarter valued at approximately $613,000. Finally, One68 Global Capital LLC acquired a new stake in Evolent Health in the fourth quarter valued at approximately $4,061,000.

Analysts Set New Price Targets

EVH has been the topic of several research analyst reports. UBS Group raised their price objective on Evolent Health from $14.00 to $15.00 and gave the company a "buy" rating in a report on Friday, May 9th. Truist Financial raised their price objective on Evolent Health from $14.00 to $16.00 and gave the company a "buy" rating in a report on Thursday, July 17th. JMP Securities reissued a "market outperform" rating and issued a $13.00 price objective on shares of Evolent Health in a report on Friday, June 20th. Piper Sandler raised their price objective on Evolent Health from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Thursday. Finally, Needham & Company LLC reissued a "buy" rating and issued a $15.00 price objective on shares of Evolent Health in a report on Tuesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, Evolent Health presently has an average rating of "Buy" and an average price target of $18.07.

Evolent Health Price Performance

Shares of NYSE:EVH traded up $0.05 during trading on Thursday, reaching $9.67. The stock had a trading volume of 2,236,506 shares, compared to its average volume of 3,792,961. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.01. The business has a fifty day moving average price of $10.15 and a 200-day moving average price of $9.55. The stock has a market cap of $1.14 billion, a PE ratio of -6.00 and a beta of 0.82. Evolent Health, Inc has a 1-year low of $7.06 and a 1-year high of $32.35.

Evolent Health (NYSE:EVH - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The technology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.20). The firm had revenue of $444.33 million during the quarter, compared to analyst estimates of $459.43 million. Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%.The business's revenue was down 31.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.30 earnings per share. Evolent Health has set its Q3 2025 guidance at EPS. On average, equities analysts forecast that Evolent Health, Inc will post 0.08 earnings per share for the current fiscal year.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.